{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:21:39Z","timestamp":1777288899176,"version":"3.51.4"},"reference-count":16,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mirt"],"DOI":"10.4274\/mirt.galenos.2024.78557","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T12:09:48Z","timestamp":1737547788000},"source":"Crossref","is-referenced-by-count":1,"title":["Relationship of Plasma Cell Infiltration Rates with 18F-FDG PET\/CT Data and Hematological Parameters in Multiple Myeloma"],"prefix":"10.4274","author":[{"given":"\u00d6zge","family":"Ula\u015f Babacan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zekiye","family":"Hasbek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatice","family":"Terzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/bjh.14193","article-title":"Multiple myeloma: practice patterns across Europe","volume":"175","author":"Raab","year":"2016","unstructured":"1. Raab MS, Cavo M, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, Safaei R, Karlin L, Mateos MV, Schoen P, Yong K. Multiple myeloma: practice patterns across Europe. Br J Haematol. 2016;175:66-76.","journal-title":"Br J Haematol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","unstructured":"2. Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43:676-681.","journal-title":"Semin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","unstructured":"3. Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, Foreman K, Gupta R, Harvey J, Hosgood HD, Jakovljevic M, Khader Y, Linn S, Lad D, Mantovani L, Nong VM, Mokdad A, Naghavi M, Postma M, Roshandel G, Shackelford K, Sisay M, Nguyen CT, Tran TT, Xuan BT, Ukwaja KN, Vollset SE, Weiderpass E, Libby EN, Fitzmaurice C. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4:1221-1227.","journal-title":"JAMA Oncol"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Medical Masterclass contributors; Firth J. Haematology: multiple myeloma. Clin Med (Lond). 2019;19:58-60.","DOI":"10.7861\/clinmedicine.19-1-58"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, Costello C, Devarakonda S, Elsedawy N, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Liedtke M, Martin T, Omel J, Sborov D, Shain K, Stockerl-Goldstein K, Weber D, Berardi RA, Kumar R, Kumar SK. NCCN Guidelines\u00ae Insights: Multiple Myeloma, Version 3.2022. J Natl Compr Canc Netw. 2022;20:8-19.","DOI":"10.6004\/jnccn.2022.0002"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Nanni C, Zamagni E. Therapy assessment in multiple myeloma with PET. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):111-117.","DOI":"10.1007\/s00259-017-3730-4"},{"key":"ref6","unstructured":"7. Beyer T, Townsend DW, Blodgett TM. Dual-modality PET\/CT tomography for clinical oncology. Q J Nucl Med. 2022;46:24-34."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10238-014-0308-3","article-title":"18F-FDG PET\/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders","volume":"15","author":"Dammacco","year":"2015","unstructured":"8. Dammacco F, Rubini G, Ferrari C, Vacca A, Racanelli V. 18F-FDG PET\/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders. Clin Exp Med. 2015;15:1-18.","journal-title":"Clin Exp Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00256-010-1088-9","article-title":"The value of FDG PET\/CT in the initial staging and bone marrow involvement of patients with multiple myeloma","volume":"40","author":"Sager","year":"2011","unstructured":"9. Sager S, Erg\u00fcl N, Ciftci H, Cetin G, G\u00fcner SI, Cermik TF. The value of FDG PET\/CT in the initial staging and bone marrow involvement of patients with multiple myeloma. Skeletal Radiol. 2011;40:843-847.","journal-title":"Skeletal Radiol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00277-010-1037-7","article-title":"F-18 FDG uptake of bone marrow on PET\/CT scan: it's correlation with CD38\/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma","volume":"90","author":"Ak","year":"2011","unstructured":"10. Ak I, Gulbas Z. F-18 FDG uptake of bone marrow on PET\/CT scan: it's correlation with CD38\/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma. Ann Hematol. 2011;90:81-87.","journal-title":"Ann Hematol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.4274\/tjh.2017.0372","article-title":"Correlation between baseline 18F-FDG PET\/CT findings and CD38- and CD138-expressing myeloma cells in bone marrow and clinical parameters in patients with multiple myeloma","volume":"35","author":"Cengiz","year":"2018","unstructured":"11. Cengiz A, Arda H\u00dc, D\u00f6\u011fer F, Yava\u015fo\u011flu \u0130, Y\u00fcrekli Y, Bolaman AZ. Correlation between baseline 18F-FDG PET\/CT findings and CD38- and CD138-expressing myeloma cells in bone marrow and clinical parameters in patients with multiple myeloma. Turk J Haematol. 2018;35:175-180.","journal-title":"Turk J Haematol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3904\/kjim.2016.054","article-title":"Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma","volume":"32","author":"Kim","year":"2017","unstructured":"12. Kim DS, Yu ES, Kang KW, Lee SR, Park Y, Sung HJ, Choi CW, Kim BS. Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma. Korean J Intern Med. 2017;32:711-721.","journal-title":"Korean J Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"18792","DOI":"10.18632\/oncotarget.13320","article-title":"Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma","volume":"8","author":"Shi","year":"2017","unstructured":"13. Shi L, Qin X, Wang H, Xia Y, Li Y, Chen X, Shang L, Tai YT, Feng X, Acharya P, Acharya C, Xu Y, Deng S, Hao M, Zou D, Zhao Y, Ru K, Qiu L, An G. Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma. Oncotarget. 2017;8: 18792-18801.","journal-title":"Oncotarget"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2329029","DOI":"10.1080\/16078454.2024.2329029","article-title":"Construction and validation of an 18F-FDG-PET\/CT-based prognostic model to predict progression-free survival in newly diagnosed multiple myeloma patients","volume":"29","author":"Dong","year":"2024","unstructured":"14. Dong X, Wang R, Ying X, Xu J, Yan J, Xu P, Peng Y, Chen B. Construction and validation of an 18F-FDG-PET\/CT-based prognostic model to predict progression-free survival in newly diagnosed multiple myeloma patients. Hematology. 2024;29:2329029.","journal-title":"Hematology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"9409","DOI":"10.2147\/CMAR.S227671","article-title":"Prognostic significance of the inflammatory index-based scoring system in patients preliminarily diagnosed with multiple myeloma in the bortezomib-based chemotherapy era","volume":"11","author":"Liu","year":"2019","unstructured":"15. Liu S, Shi J, Guo H, Xu F, Wei M, Sun K, Chen Y. Prognostic significance of the inflammatory index-based scoring system in patients preliminarily diagnosed with multiple myeloma in the bortezomib-based chemotherapy era. Cancer Manag Res. 2019;11:9409-9420.","journal-title":"Cancer Manag Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/JIR.S390279","article-title":"Inflammatory and Nutritional Scoring System for Predicting Prognosis in Patients with Newly Diagnosed Multiple Myeloma","volume":"16","author":"Zhang","year":"2023","unstructured":"16. Zhang L, Chen S, Wang W, Wang Y, Liang Y. Inflammatory and Nutritional Scoring System for Predicting Prognosis in Patients with Newly Diagnosed Multiple Myeloma. J Inflamm Res. 2023;16:7-17.","journal-title":"J Inflamm Res"}],"container-title":["Molecular Imaging and Radionuclide Therapy"],"original-title":[],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T07:18:18Z","timestamp":1739171898000},"score":1,"resource":{"primary":{"URL":"https:\/\/mirt.tsnmjournals.org\/articles\/relationship-of-plasma-cell-infiltration-rates-with-lesssupgreater18lesssupgreaterf-fdg-petct-data-and-hematological-parameters-in-multiple-myeloma\/doi\/mirt.galenos.2024.78557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":16,"URL":"https:\/\/doi.org\/10.4274\/mirt.galenos.2024.78557","relation":{},"ISSN":["2146-1414","2147-1959"],"issn-type":[{"value":"2146-1414","type":"print"},{"value":"2147-1959","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]}}}